Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Trastuzumab Deruxtecan Expands the Targeted Landscape for HER2-mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses treatment considerations for the integration of trastuzumab deruxtecan into practice and what this approval signals for the future of the field.

FDA Grants Orphan Drug Designation to Fixed-Dose Senaparib/Temozolomide Combo for SCLC

August 19th 2022

The FDA has granted an orphan drug designation to the fixed-dose combination capsule of the PARP inhibitor senaparib and temozolomide for the treatment of adult patients with small cell lung cancer.

Immunotherapy Combinations Launch Into Earlier Lines and Signal Success in Metastatic Solid Tumors

August 17th 2022

Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.

Liquid Biopsy Assay Expands Offerings to Include MRD, Disease Recurrence Detection in Early-Stage Breast and Lung Cancer

August 16th 2022

The Guardant Reveal assay has been expanded for the detection of minimal residual disease and disease recurrence in patients with early-stage breast cancer and lung cancer.

FDA Green Lights NGS-Based Companion Diagnostic for Trastuzumab Deruxtecan in HER2-Mutated NSCLC

August 16th 2022

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with NSCLC harboring an activating HER2 mutation who may derive clinical benefit from treatment with fam-trastuzumab deruxtecan-nxki.

Looking Toward the Future Management of Non–Small Cell Lung Cancer

August 16th 2022

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

August 16th 2022

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Canakinumab Fails to Meet DFS End Point in Resected NSCLC

August 15th 2022

The anti–interleukin-1β monoclonal antibody canakinumab did not generate a disease-free survival benefit vs placebo in adult patients with stages II to IIIA and IIIB completely resected non–small cell lung cancer, failing to meet the primary end point of the phase 3 CANOPY-A trial.

Audience Q&A: Emerging Therapeutic Targets in Advanced NSCLC

August 12th 2022

Closing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.

FDA Approves Trastuzumab Deruxtecan for HER2-Mutant NSCLC

August 11th 2022

The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received previous systemic therapy.

FDA Grants Regular Approval to Capmatinib for METex14+ NSCLC

August 11th 2022

The FDA has granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test.

Clinical Practice Pearls and the Future of SCLC

August 11th 2022

The panel shares clinical pearls for community oncologists treating small cell lung cancer.

Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLC

August 11th 2022

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.

Investigational Agents in SCLC in the Second Line Setting and Beyond

August 11th 2022

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

August 11th 2022

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Durvalumab Plus Concurrent Radiotherapy Meets PFS End Point in Locally Advanced NSCLC

August 9th 2022

Treatment with durvalumab and concurrent radiotherapy provided a significant benefit in progression-free survival in patients with locally advanced non–small cell lung cancer, meeting the primary end point of the phase 2 DOLPHIN trial.

First-line Avelumab Elicits Numeric But Not Significant Survival Benefit Vs Chemo in Advanced PD-L1+ NSCLC

August 9th 2022

Although frontline treatment with avelumab resulted in a longer overall survival and progression-free survival than that observed with platinum-based chemotherapy in patients with advanced non–small cell lung cancer and high PD-L1 positivity, this difference did not achieve statistical significance.

Single-Agent Sunvozertinib Elicits Responses in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations

August 9th 2022

Sunvozertinib monotherapy produced meaningful responses in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior treatment with platinum-based chemotherapy, according to pooled data from the phase 1 WU-KONG1 and WU-KONG2 trials, plus the phase 2 WU-KONG6 trial.

Dr. Sheffield on the Economic Cost of Delaying of Treatment in NSCLC

August 9th 2022

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

August 9th 2022

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.